This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): IDEC-C2B8, MabThera, RG105, rituximab, Ristova (India)
Description: Rituxan, the first monoclonal antibody approved to treat cancer, has been extremely successful as a treatment for patients with non-Hodgkin lymphoma (NHL). The antibody binds to the CD20 antigen present on B cells and B cell tumors, leading to the elimination of these cells.
A subcutaneous form of Rituxan is also in development.
Revenue splits for this drug are BioMedTracker estimates. Historical revenues and forecasts also include the subcutaneous formulation.
IDEC partnered with Genentech in March 1995 to develop and commercialize Rituxan. IDEC andGenentech agreed to co-promote Rituxan in the United States and Genentech received the exclusive rights to Rituxan outside of the U.S. with IDEC receiving a royalty from all non-U.S. sales. Upon the occurrence of certain events that constitute a change of control of IDEC, Genentech may elect to present an offer to IDEC to purchase IDEC's co-promotion rights.
In November of 1995, this agreement was amended to give Zenyaku Kogyo Co. Ltd. the rights tocommercialize Rituxan in Japan. Genentech has licensed to F. Hoffman LaRoche the rights to Rituxan outside the U.S. and Japan.
IDEC receives royalties on all sales outside the U.S. IDEC receives a share of the profits (net sales less manufacturing expense, third party royalties or commissions,...See full deal structure in Biomedtracker
Partners: Zenyaku Kogyo Co., Ltd. Biogen, Inc.
Additional information available to subscribers only: